Strong ESMO Data Fail to Lift Tango Therapeutics as Investors Sell the News

Updated Phase 1/2 data at ESMO showed 82% ORR and 88% 9-month PFS with vopimetostat plus daraxonrasib in previously treated MTAP-deleted RAS-mutant PDAC.